ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Primaire myelofibrose (PMF) Richtlijnen en literatuur

Richtlijnen

Klik HIER voor de richtlijn 'Primaire myelofibrose' van de HOVON CML - MPN werkgroep.

Literatuur  

  1. Arber D.A. et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical and genomic data. Blood 2022; 140(11):1200-1228
  2. Khoury et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic dendritic neoplasms - Leukemia 2022; 36:1703-1719
  3. Barosi G. et al. Proposed criteria for the diagnosis of post- polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22:437-38
  4. Cervantes F et al. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol 2015; 94:1791-96
  5. Emanuel RM et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012; 30(33):4098-103
  6. Gagelmann N et al: Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood 2019; 133(20):2233-42
  7. Gangat N et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29(4):392-7
  8. Geyer HL et al. Distinct clustering of symptomatic burden among myelo­prolifera­tive neoplasm patients: retrospective assessment in 1470 patients. Blood 2014; 123(24):3803-10
  9. Guglielmelli P et al. MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol 2018; 36(4):310-31
  10. Gupta V et al. Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediate- or high-risk myelo­fibrosis previously treated with ruxolitinib. Clin Lymph Myeloma Leuk 2020; 20 (suppl 1):S331-32
  11. Hamulyak EN et al. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms. Blood Advances 2021; 5(1):113-121
  12. Harrison C et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open- label, non-randomised, phase 2, multicentre study. Lancet Haematol 2017; 4:e317-24
  13. Hernández-Boluda JC et al. Prognostic risk models for transplant decision-making in myelofibrosis. Ann Hematol 2018; 97(5):813-20
  14. Hernández-Boluda JC et al. Predictive factors for anemia response to erythro­poiesis-stimulating agents in myelofibrosis. Eur J Haematol 2017; 98(4):407-14
  15. Kerbauy DM et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombo­cythemia. Biol Blood Marrow Transplant 2007; 13(3):355-65
  16. Kröger N et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood 2015; 125:3347-50
  17. Kröger N et al: Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemie 2021; 35(12):3551-60
  18. Racca C et al. Aspirin intake in the morning is associated with suboptimal platelet inhibition, as measured by serum thromboxane B2, during infarct-prone early-morning hours. Platelets 2019; 30(7):871-77
  19. Rocca B et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood 2020; 136(2):171-82
  20. Riva N et al. Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res 2012; 130 Suppl 1:S1-3
  21. Rottenstreich A et al. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. Eur J Intern Med 2017; 41:49-54
  22. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition, vol. 2, 2008
  23. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition, vol. 2, 2017
  24. Tiede A et al. How I treat the acquired von Willebrand syndrome. Blood 2011; 117(25):6777-6785
  25. Hermandez-Boluda et al. Use of machine learning techniques to predict poor survival after hamtopoietic cell transplantation for myelofibrosis. Blood 2025; 145(26):3199-3152
  26. Tefferi et al. MIPSS70+ Version 2.0: Mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018; 36(17):1769-1770

 

Ga terug naar de PMF homepage of lees meer over PMF:

Ga terug naar de algemene homepage Behandelprotocollen.